Anti-HCV drugs in the pipeline

Current Opinion in Virology

Volumn 1, Issue 6, 2011, Pages 607-616

  Yang, Priscilla L ^a   Gao, Min ^b   Lin, Kai ^c   Liu, Qingsong ^a   Villareal, Valerie A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 072; ABT 333; ABT 450; ACH 1625; ACH 2684; ALISPORIVIR; ANA 598; ANA 773; ANTIVIRUS AGENT; ASUNAPREVIR; BI 201335; BI 207127; BMS 790052; BOCEPREVIR; CF 102; CTS 1027; CYCLOPHILIN; CYT 107; DANOPREVIR; FILIBUVIR; GOLOTIMOD; GS 5885; GS 6620; GS 9256; GSK 2485852A; IDX 184; INX 189; ITX 5061; JKB 122; MERICITABINE; MIRAVIRSEN; MK 5172; NITAZOXANIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; NOV 205; PEGINTERFERON; PPI 461; PSI 7977; PSI 938; PYN 17; RIBAVIRIN; SCY 635; TEGOBUVIR; TELAPREVIR; TMC 435350; TMC 649128; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANIPREVIR; VX 222; VX 759;

ARTICLE; CROSS RESISTANCE; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS INHIBITION;

EID: 82955236108     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2011.10.019     Document Type: Review

References (90)

1. C.A. Lesburg, M.B. Cable, E. Ferrari, Z. Hong, A.F. Mannarino, and P.C. Weber Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat Struct Biol 6 1999 937 943 (Pubitemid 29463307)
2. S. Bressanelli, L. Tomei, A. Roussel, I. Incitti, R.L. Vitale, M. Mathieu, R. De Francesco, and R.A. Rey Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus Proc Natl Acad Sci USA 96 1999 13034 13039
3. S. Le Pogam, A. Seshaadri, A. Ewing, H. Kang, A. Kosaka, J.M. Yan, M. Berrey, B. Symonds, A. De La Rosa, and N. Cammack RG7128 alone or in combination with pegylated interferon-alpha2a and ribavirin prevents hepatitis C virus (HCV) replication and selection of resistant variants in HCV-infected patients J Infect Dis 202 2010 1510 1519
4. L. Delang, I. Vliegen, M. Froeyen, and J. Neyts Comparative study of the genetic barriers and pathways towards resistance of selective inhibitors of hepatitis C virus replication Antimicrob Agents Chemother 55 2011 4103 4113
5. M.F. McCown, S. Rajyaguru, S. Le Pogam, S. Ali, W.R. Jiang, H. Kang, J. Symons, N. Cammack, and I. Najera The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors Antimicrob Agents Chemother 52 2008 1604 1612 (Pubitemid 351614649)
6. O. Nyanguile, B. Devogelaere, L. Vijgen, W. Van den Broeck, F. Pauwels, M.D. Cummings, H.L. De Bondt, A.M. Vos, J.M. Berke, and O. Lenz 1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus J Virol 84 2010 2923 2934
7. I.H. Shih, I. Vliegen, B. Peng, H. Yang, C. Hebner, J. Paeshuyse, G. Purstinger, M. Fenaux, Y. Tian, and E. Mabery Mechanistic characterization of GS-9190 (Tegobuvir), a novel nonnucleoside inhibitor of hepatitis C virus NS5B polymerase Antimicrob Agents Chemother 55 2011 4196 4203
8. E.J. Graham, R. Hunt, S.M. Shaw, C. Pickford, J. Hammond, M. Westby, and P. Targett-Adams Colony-forming assays reveal enhanced suppression of hepatitis C virus replication using combinations of direct-acting antivirals J Virol Methods 174 2011 153 157
9. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, S.K. Young, B. Lee, D. Heckerman, J. Carlson, and L.L. Reyor Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
10. F. Legrand-Abravanel, C. Henquell, H. Le Guillou-Guillemette, V. Balan, A. Mirand, M. Dubois, F. Lunel-Fabiani, C. Payan, and J. Izopet Naturally occurring substitutions conferring resistance to hepatitis C virus polymerase inhibitors in treatment-naive patients infected with genotypes 1-5 Antivir Ther 14 2009 723 730
11. S. Le Pogam, A. Seshaadri, A. Kosaka, S. Chiu, H. Kang, S. Hu, S. Rajyaguru, J. Symons, N. Cammack, and I. Najera Existence of hepatitis C virus NS5B variants naturally resistant to non-nucleoside, but not to nucleoside, polymerase inhibitors among untreated patients J Antimicrob Chemother 61 2008 1205 1216 (Pubitemid 351753583)
12. F. Legrand-Abravanel, F. Nicot, and J. Izopet New NS5B polymerase inhibitors for hepatitis C Expert Opin Investig Drugs 19 2010 963 975
13. R. Reddy, M. Rodriguez-Torres, E.J. Gane, R. Robson, J. Lezalari, G.T. Everson, E. DeJesus, J.G. McHutchison, H.E. Vargas, and A. Beard Antiviral activity, pharmacokinetics, safety, and tolerability of R7128, a novel nucleoside HCV RNA polymerase inhibitor, following multiple, ascending, oral doses in patients with HCV genotype 1 infection who have failed prior interferon therapy Hepatology 46 2007 862A
14. E. Murakami, H. Bao, M. Ramesh, T.R. McBrayer, T. Whitaker, H.M. Micolochick Steuer, R.F. Schinazi, L.J. Stuyver, A. Obikhod, and M.J. Otto Mechanism of activation of beta-D-2′-deoxy-2′-fluoro-2′-c- methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase Antimicrob Agents Chemother 51 2007 503 509 (Pubitemid 46185267)
15. P. Pockros, D. Jensen, N. Tsai, R.M. Taylor, A. Ramji, C. Cooper, R. Dickson, A. Tice, S. Stancic, and D. Ipe First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis for the JUMP-C trial J Hepatol 54 2011 S538
16. E.J. Gane, M. Rodriguez-Torres, D. Nelson, I.M. Jacobson, J.G. McHutchison, A. Duca, R. Hyland, G. Hill, E. Albanis, and B. Symonds Sustained virology response (SVR) following RG7128 1500 mg BID/PEG-IFN/RBV for 28 days in HCV genotype 2/3 prior non-responders J Hepatol 42 2010 S16
17. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, R. Elston, D. Ipe, P.N. Morcos, L. Baher, and I. Najera Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
18. G. Migliaccio, J.E. Tomassini, S.S. Carroll, L. Tomei, S. Altamura, B. Bhat, L. Bartholomew, M.R. Bosserman, A. Ceccacci, and L.F. Colwell Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro J Biol Chem 278 2003 49164 49170
19. S.W. Ludmerer, D.J. Graham, E. Boots, E.M. Murray, A. Simcoe, E.J. Markel, J.A. Grobler, O.A. Flores, D.B. Olsen, and D.J. Hazuda Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay Antimicrob Agents Chemother 49 2005 2059 2069 (Pubitemid 40631625)
20. A.M. Lam, C. Espiritu, E. Murakami, V. Zennou, S. Bansal, H.M. Micolochick Steuer, C. Niu, M. Keilman, H. Bao, and N. Bourne Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C- methylguanosine Antimicrob Agents Chemother 55 2011 2566 2575
21. A. Macdonald, and M. Harris Hepatitis C virus NS5A: tales of a promiscuous protein J Gen Virol 85 2004 2485 2502 (Pubitemid 39214345)
22. B. Buckman Discovery of potent NS5A inhibitors with favorable pharmacokinetics and robust activity in an HCV animal model The 5th International Workshop on Clinical Pharmacology of Hepatitis Therapy Boston, MA 2010
23. J. Bechtel, R. Crosby, A. Wang, E. Woldu, S. Van Horn, J. Horton, K. Creech, L.H. Caballo, C. Voitenleitner, and J. Vamathevan In vitro profiling of GSK2336805, a potent and selective inhibitor of HCV NS5A J Hepatol 54 2011 S307 S308
24. E.O Dumas, A. Lawal, R.M. Menon, T. Podsadecki, W. Awni, S. Dutta, and L. Williams Pharmacokinetics, safety and tolerability of the HCV NS5A inhibitor ABT-267 following single and multiple doses in healthy adult volunteers J Hepatol 54 2011 S475 S476
25. P. Targett-Adams, E.J. Graham, J. Middleton, A. Palmer, S.M. Shaw, H. Lavender, P. Brain, T.D. Tran, L.H. Jones, and F. Wakenhut Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action J Virol 85 2011 6353 6368
26. Bruce J, Milbank J, Pryde DC, Tran TD: Hepatitis C Virus Inhibitors. US Patent 2011, WO/2011/004276.
27. C.B. Dousson, C. Chapron, D. Standring, J.P. Bilello, J. McCarville, M. La Colla, M. Seifer, C. Parsy, D. Dukhan, and C. Pierra Idenix NS5A HCV replication inhibitors with low picomolar, pan-genotypic in vitro antiviral activity J Hepatol 54 2011 S326 S327
28. M. Huang, G. Yang, D. Patel, Y. Zhao, J. Fabrycki, C. Marlor, J. Rivera, K. Stauber, V. Gadhachanda, and J. Wiles ACH-2928: a novel highly potent HCV NS5A inhibitor with favorable preclinical characteristics J Hepatol 54 2011 S479
29. L.J. Jiang, S. Liu, T. Phan, C. Owens, B. Brasher, A. Polemeropoulos, X. Luo, K. Hoang, M. Wang, and X. Peng A potent highly HCV NS5A inhibitor EDP-239 with favorable preclinical pharmacokinetics J Hepatol 54 2011 S479
30. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, R.A. Fridell, M.H. Serrano-Wu, D.R. Langley, J.H. Sun, and D.R. O'Boyle 2nd Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
31. E. Lawitz, D. Gruener, J. Hill, T. Marbury, S. Komjathy, M. DeMicco, A. Murillo, F. Jenkin, K. Kim, and J. Simpson Three-day, dose-ranging study of the HCV NS5A inhibitor GS-5885 J Hepatol 54 2011 S481 S482
32. R. Colonno, E. Peng, M. Bencsik, N. Huang, M. Zhong, A. Huq, Q. Huang, J. Williams, and L. Li Identification and characterization of PPI-461, a potent and selective HCV NS5A inhibitor with activity against all HCV genotypes J Hepatol 52 2010 S14 S15
33. E. Gane, G.R. Foster, J. Cianciara, C. Stedman, S. Ryder, M. Buti, E. Clark, and D. Tait Antiviral activity, pharmacokinetics, and tolerability of AZD7295, a novel NS5A inhibitor, in a placebo-controlled multiple ascending dose study in HCV genotype 1 and 3 patients J Hepatol 52 2010 S464
34. J.A. Lemm, J.E. Leet, D.R. O'Boyle 2nd, J.L. Romine, X.S. Huang, D.R. Schroeder, J. Alberts, J.L. Cantone, J.H. Sun, and P.T. Nower Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures Antimicrob Agents Chemother 55 2011 3795 3802
35. R.A. Fridell, D. Qiu, L. Valera, C. Wang, R.E. Rose, and M. Gao Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 J Virol 85 2011 7312 7320
36. T.L. Tellinghuisen, J. Marcotrigiano, and C.M. Rice Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase Nature 435 2005 374 379 (Pubitemid 40745549)
37. R.A. Love, O. Brodsky, M.J. Hickey, P.A. Wells, and C.N. Cronin Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus J Virol 83 2009 4395 4403
38. S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, H.A. Tatum, C. Hezode, J.K. Lim, J.P. Bronowicki, and G.A. Abrams First report of SVR12 for a NS5A replication complex inhibitor BMS-790052 in combination with PEG-IFN alpha-2A and RBV: phase 2A trial in treatment-naive HCV-genotype 1 subjects J Hepatol 52 2010 S544 S545
39. R.E. Nettles, M. Gao, M. Bifano, E. Chung, A. Persson, T.C. Marbury, R. Goldwater, M.P. DeMicco, M. Rodriguez-Torres, and A. Vutikullird Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 2011 10.1002/hep.24609 [Epub ahead of print]
40. R.A. Fridell, C. Wang, J.-H. Sun, D.R. O'Boyle, P.T. Nower, L. Valera, D. Qiu, S. Roberts, X. Huang, and B. Kienzle Genotypic and phenotypic analysis of variants resistant to HCV NS5A replication complex inhibitor BMS-790052: in vitro and in vivo correlations Hepatology 2011 10.1002/hep.24594 [Epub ahead of print]
41. R.A. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system Antimicrob Agents Chemother 54 2010 3641 3650
42. A. Kaul, S. Stauffer, C. Berger, T. Pertel, J. Schmitt, S. Kallis, M. Zayas, V. Lohmann, J. Luban, and R. Bartenschlager Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 2009 e1000546
43. F. Yang, J.M. Robotham, H.B. Nelson, A. Irsigler, R. Kenworthy, and H. Tang Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro J Virol 82 2008 5269 5278 (Pubitemid 351705235)
44. U. Chatterji, M. Bobardt, S. Selvarajah, F. Yang, H. Tang, N. Sakamoto, G. Vuagniaux, T. Parkinson, and P. Gallay The isomerase active site of cyclophilin A is critical for hepatitis C virus replication J Biol Chem 284 2009 16998 17005
45. S. Ciesek, E. Steinmann, H. Wedemeyer, M.P. Manns, J. Neyts, N. Tautz, V. Madan, R. Bartenschlager, T. von Hahn, and T. Pietschmann Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A Hepatology 50 2009 1638 1645
46. L.A. Gaither, J. Borawski, L.J. Anderson, K.A. Balabanis, P. Devay, G. Joberty, C. Rau, M. Schirle, T. Bouwmeester, and C. Mickanin Multiple cyclophilins involved in different cellular pathways mediate HCV replication Virology 397 2010 43 55
47. X. Hanoulle, A. Badillo, J.M. Wieruszeski, D. Verdegem, I. Landrieu, R. Bartenschlager, F. Penin, and G. Lippens Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B J Biol Chem 284 2009 13589 13601
48. U. Chatterji, M.D. Bobardt, P. Lim, and P.A. Gallay Cyclophilin A-independent recruitment of NS5A and NS5B into hepatitis C virus replication complexes J Gen Virol 91 2010 1189 1193
49. K. Watashi, N. Ishii, M. Hijikata, D. Inoue, T. Murata, Y. Miyanari, and K. Shimotohno Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase Mol Cell 19 2005 111 122 (Pubitemid 40884662)
50. F. Fernandes, D.S. Poole, S. Hoover, R. Middleton, A.C. Andrei, J. Gerstner, and R. Striker Sensitivity of hepatitis C virus to cyclosporine A depends on nonstructural proteins NS5A and NS5B Hepatology 46 2007 1026 1033 (Pubitemid 350144767)
51. J.A. Heck, X. Meng, and D.N. Frick Cyclophilin B stimulates RNA synthesis by the HCV RNA dependent RNA polymerase Biochem Pharmacol 77 2009 1173 1180
52. Z. Liu, F. Yang, J.M. Robotham, and H. Tang Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex J Virol 83 2009 6554 6565
53. K. Goto, K. Watashi, D. Inoue, M. Hijikata, and K. Shimotohno Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor Cancer Sci 100 2009 1943 1950
54. J.M. Robida, H.B. Nelson, Z. Liu, and H. Tang Characterization of hepatitis C virus subgenomic replicon resistance to cyclosporine in vitro J Virol 81 2007 5829 5840 (Pubitemid 46847020)
55. F. Yang, J.M. Robotham, H. Grise, S. Frausto, V. Madan, M. Zayas, R. Bartenschlager, M. Robinson, A.E. Greenstein, and A. Nag A major determinant of cyclophilin dependence and cyclosporine susceptibility of hepatitis C virus identified by a genetic approach PLoS Pathog 6 2010 e1001118
56. L. Coelmont, X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M. Bobardt, P. Lim, I. Vliegen, J. Paeshuyse, and G. Vuagniaux DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A PLoS ONE 5 2010 e13687
57. D. Verdegem, A. Badillo, J.M. Wieruszeski, I. Landrieu, A. Leroy, R. Bartenschlager, F. Penin, G. Lippens, and X. Hanoulle Domain 3 of NS5A protein from the hepatitis C virus has intrinsic alpha-helical propensity and is a substrate of cyclophilin A J Biol Chem 286 2011 20441 20454
58. T.L. Foster, P. Gallay, N.J. Stonehouse, and M. Harris Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner J Virol 85 2011 7460 7464
59. S. Ma, J.E. Boerner, C. TiongYip, B. Weidmann, N.S. Ryder, M.P. Cooreman, and K. Lin NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon Antimicrob Agents Chemother 50 2006 2976 2982 (Pubitemid 44396401)
60. R. Flisiak, S.V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, M. Pawlowska, J.E. Heathcote, G. Mazzella, C. Vandelli, and V. Nicolas- Métral The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients Hepatology 49 2009 1460 1468
61. S. Hopkins, D. Heuman, E. Gavis, J. Lalezari, E. Glutzer, B. DiMassimo, P. Rusnak, S. Wring, C. Smitley, and Y. Ribeill Safety, plasma pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with chronic hepatitis C virus infection J Hepatol 50 2009 S36
62. E. Lawitz, E. Godofsky, R. Rouzier, T. Marbury, T. Nguyen, J. Ke, M. Huang, J. Praestgaard, D. Serra, and T.G. Evans Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy Antiviral Res 89 2011 238 245
63. J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
64. R. Flisiak, A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak, J. Higersberger, and J. Kierkus The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 47 2008 817 826 (Pubitemid 351449673)
65. R. Flisiak, J.M. Pawlowska, R. Crabbé, W. Calistru, W. Kryczka, D. Haüssinger, G. Mazzella, M. Romero-Gomez, D. Purcea, and G. Vuagniaux Once-daily alisporivir (DEB025) plus PEG-IFN-α-2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment naïve patients J Hepatol 54 2011 S2
66. S. Hopkins, B. Scorneaux, Z. Huang, M.G. Murray, S. Wring, C. Smitley, R. Harris, F. Erdmann, G. Fischer, and Y. Ribeill SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob Agents Chemother 54 2010 660 672
67. J.E. Mathy, S. Ma, T. Compton, and K. Lin Combinations of cyclophilin inhibitor NIM811 with hepatitis C virus NS3-4A protease or NS5B polymerase inhibitors enhance antiviral activity and suppress the emergence of resistance Antimicrob Agents Chemother 52 2008 3267 3275
68. X. Puyang, D.L. Poulin, J.E. Mathy, L.J. Anderson, S. Ma, Z. Fang, S. Zhu, K. Lin, R. Fujimoto, and T. Compton Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors Antimicrob Agents Chemother 54 2010 1981 1987
69. C. Tiongyip, C.T. Jones, Y. Tang, J. Snoeck, A.-M. Vandamme, L. Coelmont, J. Neyts, G. Vuagniaux, R. Crabbe, and N. Naoumov Host targeting cyclophilin inhibitor alisporivir presents a high barrier to resistance with no cross-resistance to direct acting antivirals 6th International Workshop on Hepatitis C, Resistance and New Compounds Cambridge, MA 2011
70. L. Coelmont, S. Kaptein, J. Paeshuyse, I. Vliegen, J.M. Dumont, G. Vuagniaux, and J. Neyts Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 53 2009 967 976
71. D. Egger, B. Wolk, R. Gosert, L. Bianchi, H.E. Blum, D. Moradpour, and K. Bienz Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex J Virol 76 2002 5974 5984 (Pubitemid 34556292)
72. A.W. Tai, Y. Benita, L.F. Peng, S.S. Kim, N. Sakamoto, R.J. Xavier, and R.T. Chung A functional genomic screen identifies cellular cofactors of hepatitis C virus replication Cell Host Microbe 5 2009 298 307
73. K.L. Berger, J.D. Cooper, N.S. Heaton, R. Yoon, T.E. Oakland, T.X. Jordan, G. Mateu, A. Grakoui, and G. Randall Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication Proc Natl Acad Sci USA 106 2009 7577 7582
74. M. Trotard, C. Lepere-Douard, M. Regeard, C. Piquet-Pellorce, D. Lavillette, F.L. Cosset, P. Gripon, and J. Le Seyec Kinases required in hepatitis C virus entry and replication highlighted by small interference RNA screening FASEB J 23 2009 3780 3789
75. Q. Li, A.L. Brass, A. Ng, Z. Hu, R.J. Xavier, T.J. Liang, and S.J. Elledge A genome-wide genetic screen for host factors required for hepatitis C virus propagation Proc Natl Acad Sci USA 106 2009 16410 16415
76. J. Borawski, P. Troke, X. Puyang, V. Gibaja, S. Zhao, C. Mickanin, J. Leighton-Davies, C.J. Wilson, V. Myer, and I. Cornellataracido Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication J Virol 83 2009 10058 10074
77. F.H. Vaillancourt, L. Pilote, M. Cartier, J. Lippens, M. Liuzzi, R.C. Bethell, M.G. Cordingley, and G. Kukolj Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication Virology 387 2009 5 10
78. S. Einav, D. Gerber, P.D. Bryson, E.H. Sklan, M. Elazar, S.J. Maerkl, J.S. Glenn, and S.R. Quake Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis Nat Biotechnol 26 2008 1019 1027
79. R. Hamatake, J. Pouliot, M. Thomson, M. Xie, J. Johnson, A. Peat, C. Roberts, A. Mathis, P. Xiong, and R. Peterson The efficacy of an NS4B inhibitor in HCV infected PXB-mice 18th International Symposium on HCV and Related Viruses Seattle, Washington 2011
80. C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA Science 309 2005 1577 1581 (Pubitemid 41266486)
81. C.L. Jopling, S. Schutz, and P. Sarnow Position-dependent function for a tandem microRNA miR-122-binding site located in the hepatitis C virus RNA genome Cell Host Microbe 4 2008 77 85 (Pubitemid 351944051)
82. R.K. Jangra, M. Yi, and S.M. Lemon Regulation of hepatitis C virus translation and infectious virus production by the microRNA miR-122 J Virol 84 2010 6615 6625
83. R.E. Lanford, E.S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M.E. Munk, S. Kauppinen, and H. Orum Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201
84. E. Herker, C. Harris, C. Hernandez, A. Carpentier, K. Kaehlcke, A.R. Rosenberg, R.V. Farese Jr., and M. Ott Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1 Nat Med 16 2010 1295 1298
85. M. Flint, S. Mullen, A.M. Deatly, W. Chen, L.Z. Miller, R. Ralston, C. Broom, E.A. Emini, and A.Y. Howe Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034) Antimicrob Agents Chemother 53 2009 401 411
86. G.R. Foster, P. Buggisch, P. Marcellin, S. Zeuzem, K. Agarwal, M. Manns, D. Sereni, H. Klinker, C. Moreno, and J.P. Zarski Four-week treatment with GS-9256 and tegobuvir (GS-9190), ± RBV ± PEG, results in enhanced viral suppression on follow-up PEG/RBV therapy in genotype 1a/1b HCV patients J Hepatol 54 2011 S172
87. A.M. Di Bisceglie, D.R. Nelson, E. Gane, K. Alves, M.J. Koziel, C. De Souza, T.L. Kieffer, S. George, R.S. Kauffman, and I.M. Jacobson VX-222 with TVR alone or in combination with PEGinterferon alfa-2A and ribavirin in treatment-naive patients with chronic hepatitis C: Zenith study interim results J Hepatol 54 2011 S540
88. Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, et al.: Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI 201335, the HCV polymerase inhibitor BI 207127, and ribavirin, in patients with chronic hepatitis C: the SOUND-C1 trial. In 61th Annual Meeting of the American Association for the Study of Liver Diseases: Boston, MA; 2010.
89. E. Lawitz, M. Rodriguez-Torres, J. Denning, M. Cornpropsr, D. Clemons, L. McNair, M.M. Berrey, and W. Symonds Once daily dual-nucleotide combination of PSI-938 and PSI-7977 provides 94% HCVRNA
90. A. Lok, D. Gardiner, E. Lawitz, C. Martorell, G. Everson, R. Ghalib, R. Reindollar, V. Rustgi, F. McPhee, and M. Wind-Rotolo Quadruple therapy with BMS-790052, BMS-650032 and PEG-IFN/RBV for 24 weeks results in 100% SVR12 in HCV genotype 1 null responders J Hepatol 54 2011 S536